» Articles » PMID: 22245846

Frequent Detection of Pancreatic Lesions in Asymptomatic High-risk Individuals

Abstract

Background & Aims: The risk of pancreatic cancer is increased in patients with a strong family history of pancreatic cancer or a predisposing germline mutation. Screening can detect curable, noninvasive pancreatic neoplasms, but the optimal imaging approach is not known. We determined the baseline prevalence and characteristics of pancreatic abnormalities using 3 imaging tests to screen asymptomatic, high-risk individuals (HRIs).

Methods: We screened 225 asymptomatic adult HRIs at 5 academic US medical centers once, using computed tomography (CT), magnetic resonance imaging (MRI), and endoscopic ultrasonography (EUS). We compared results in a blinded, independent fashion.

Results: Ninety-two of 216 HRIs (42%) were found to have at least 1 pancreatic mass (84 cystic, 3 solid) or a dilated pancreatic duct (n = 5) by any of the imaging modalities. Fifty-one of the 84 HRIs with a cyst (60.7%) had multiple lesions, typically small (mean, 0.55 cm; range, 2-39 mm), in multiple locations. The prevalence of pancreatic lesions increased with age; they were detected in 14% of subjects younger than 50 years old, 34% of subjects 50-59 years old, and 53% of subjects 60-69 years old (P < .0001). CT, MRI, and EUS detected a pancreatic abnormality in 11%, 33.3%, and 42.6% of the HRIs, respectively. Among these abnormalities, proven or suspected neoplasms were identified in 85 HRIs (82 intraductal papillary mucinous neoplasms and 3 pancreatic endocrine tumors). Three of 5 HRIs who underwent pancreatic resection had high-grade dysplasia in less than 3 cm intraductal papillary mucinous neoplasms and in multiple intraepithelial neoplasias.

Conclusions: Screening of asymptomatic HRIs frequently detects small pancreatic cysts, including curable, noninvasive high-grade neoplasms. EUS and MRI detect pancreatic lesions better than CT.

Citing Articles

Pancreatic cancer: Future challenges and new perspectives for an early diagnosis.

Cocca S, Pontillo G, Lupo M, Lieto R, Marocchi M, Marsico M World J Clin Oncol. 2025; 16(2):97248.

PMID: 39995556 PMC: 11686566. DOI: 10.5306/wjco.v16.i2.97248.


Current Approaches of Pancreatic Cancer Surveillance in High-Risk Individuals.

Heller M, Mann D, Katona B J Gastrointest Cancer. 2025; 56(1):61.

PMID: 39932614 PMC: 11814005. DOI: 10.1007/s12029-025-01184-1.


Advances in Endoscopic Ultrasound in Pancreatic Cancer Screening, Diagnosis, and Palliative Care.

Zhang W, Chen J, Zhang W, Xu M Biomedicines. 2025; 13(1).

PMID: 39857661 PMC: 11762820. DOI: 10.3390/biomedicines13010076.


An Autopsy Case of Myotonic Dystrophy Type 1 With Pancreatic Intraductal Papillary Mucinous Neoplasm.

Nonaka K, Arakawa A, Hara M, Komatsu A, Nagasaka T, Kumasaka T Cureus. 2024; 16(9):e70225.

PMID: 39463607 PMC: 11512164. DOI: 10.7759/cureus.70225.


Inactivation of HIPK2 attenuates KRAS activity and prevents pancreatic tumorigenesis.

Sozzi S, Manni I, Ercolani C, Diodoro M, Bartolazzi A, Spallotta F J Exp Clin Cancer Res. 2024; 43(1):265.

PMID: 39342278 PMC: 11437985. DOI: 10.1186/s13046-024-03189-3.


References
1.
Verna E, Hwang C, Stevens P, Rotterdam H, Stavropoulos S, Sy C . Pancreatic cancer screening in a prospective cohort of high-risk patients: a comprehensive strategy of imaging and genetics. Clin Cancer Res. 2010; 16(20):5028-37. DOI: 10.1158/1078-0432.CCR-09-3209. View

2.
Laffan T, Horton K, Klein A, Berlanstein B, Siegelman S, Kawamoto S . Prevalence of unsuspected pancreatic cysts on MDCT. AJR Am J Roentgenol. 2008; 191(3):802-7. PMC: 2692243. DOI: 10.2214/AJR.07.3340. View

3.
Canto M, Goggins M, Yeo C, Griffin C, Axilbund J, Brune K . Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004; 2(7):606-21. DOI: 10.1016/s1542-3565(04)00244-7. View

4.
Brune K, Lau B, Palmisano E, Canto M, Goggins M, Hruban R . Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst. 2010; 102(2):119-26. PMC: 2808346. DOI: 10.1093/jnci/djp466. View

5.
Jones S, Hruban R, Kamiyama M, Borges M, Zhang X, Parsons D . Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science. 2009; 324(5924):217. PMC: 2684332. DOI: 10.1126/science.1171202. View